Investigator(s)
| Submitter |
Karma Galey Ministry of Health Karma Galey 
|
| Principal Investigator |
Karma Galey Ministry of Health Karma Galey
|
| Co-Investigator(s) |
Cheten Zangmo DoPH, MoH Cheten Zangmo
|
| Co-Investigator(s) |
Kuenzang Dorji RCDC, MoH Kuenzang Dorji
|
| Co-Investigator(s) |
karma Norbu HITAD, MOH karma Norbu
|
| Co-Investigator(s) |
sangay norbu HITAD, MoH sangay norbu
|
| Co-Investigator(s) |
Tshering Duba HITAD, MoH Tshering Duba
|
| Co-Investigator(s) |
Ong The Due Head of Health Financing and Health Technology Assessment Department Health Strategy and Policy Institute, Ministry of Health, Thailand. Ong The Due
|
Title(s) and abstract
| Scientific title | Cost Benefit Analysis of influenza vaccine roll out in Bhutan |
| Public title | Cost Benefit Analysis of influenza vaccine roll out in Bhutan |
| Background | The healthcare system in Bhutan operates on a three-tier structure: primary, secondary, and tertiary levels. Bhutanese citizens are entitled to free basic public healthcare services. As a landlocked country in Southeast Asia with favorable climatic conditions for influenza outbreaks, Bhutan faces significant public health challenges. |
| Objectives | 1.To evaluate the cost-benefit analysis of the influenza vaccine program in Bhutan. 2.To examine the associated medical and indirect cost of productivity lost (Hospitalization) and loss of lives due to premature deaths. 3.To evaluate the budget impact analysis of the program |
| Study Methods | A systematic process of calculating cost benefit analysis will be design and adopted to evaluate the cost, benefit, and net saving associated with influenza vaccination program. |
| Expected outcomes and use of results | At the outcome level study, measurement of both direct and indirect costs of influenza illness, such as medical cost, physician and nurse cost, lost productivity (Hospitalization), and mortality (Pre-mature deaths) will be taken into consideration to measure the benefit analysis of the program. |
| Keywords | Influenza vaccine, cost benefit analysis, direct and indirect cost. |
Research Details
| Student research | No |
| Start Date | 01-Jan-2025 |
| End Date | 31-Oct-2025 |
| Key Implementing Institution | Ministry of Health |
| Multi-country research | No |
| Nationwide research | Yes |
| Research Domain(s) | Communicable Disease Research |
| Research field(s) | Immunization/Vaccine Preventable Disease |
| Involves human subjects | Yes |
| Operational Research | |
| Data Collection | Secondary data |
| Proposal reviewed by other Committee | Approved |